Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Abstract Background The combination of Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blockade has dramatically improved the overall survival rate for malignant melanoma. Immune checkpoint blockers (ICBs) limit the tumor’s immune escape yet only for approximately a thir...

Full description

Bibliographic Details
Main Authors: Adriana Amaro, Francesco Reggiani, Daniela Fenoglio, Rosaria Gangemi, Anna Tosi, Alessia Parodi, Barbara Banelli, Valentina Rigo, Luca Mastracci, Federica Grillo, Alessandra Cereghetti, Aizhan Tastanova, Adhideb Ghosh, Fabio Sallustio, Laura Emionite, Antonio Daga, Tiziana Altosole, Gilberto Filaci, Antonio Rosato, Mitchell Levesque, Michele Maio, Ulrich Pfeffer, Michela Croce, EPigenetic Immune-oncology Consortium Airc (EPICA) consortium
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Melanoma
Guadecitabine
Anti-PD-1
Anti-CTLA-4
Tumor microenvironment
Treg
Online Access:https://doi.org/10.1186/s13046-023-02628-x

Internet

https://doi.org/10.1186/s13046-023-02628-x

Similar Items